Study	N(Drug, Pla)	Drug, dose	SMD [95% CI]
Colwell, 2024	26, 27	Fenfluramine 15mg b.i.d.	−0.03 [−0.57, 0.51]
Michely, 2022	33, 33	Citalopram 20mg/day	−0.66 [−1.16, −0.17]
Guitart−Masip, 2012	16, 20	Citalopram 24mg oral	−0.26 [−0.92, 0.40]
Beierholm, 2013	30, 30	Citalopram 24mg oral	0.26 [−0.25, 0.76]
Jepma, 2010	16, 17	Citalopram 30mg	−0.04 [−0.72, 0.64]
Guitart−Masip, 2014	27, 29	Citalopram 30mg	0.28 [−0.24, 0.81]
Guitart−Masip, 2014	27, 29	Citalopram 30mg	0.28 [−0.24, 0.81]
Luo, 2024	32, 33	Escitalopram 20mg	−3.28 [−4.02, −2.54]
Crean, 2002	20, 20	TD	0.29 [−0.33, 0.91]
Cools, 2005	10, 12	TD	1.20 [0.29, 2.12]
Roiser, 2006	30	TD	0.16 [−0.29, 0.61]
Finger, 2007	16, 19	TD	0.59 [−0.09, 1.27]
Tanaka, 2007	12, 12	TD	−0.02 [−0.82, 0.78]
Cools, 2008	12	TD	−0.02 [−0.49, 0.46]
Schweighofer, 2008	20	TD	0.77 [0.13, 1.41]
Robinson, 2012	21, 20	TD	−0.31 [−0.93, 0.30]
Seymour, 2012	15, 15	TD	1.02 [0.26, 1.78]
Geurts, 2013	45	TD	0.02 [−0.32, 0.35]
Worbe, 2014	22, 22	TD	0.24 [−0.36, 0.83]
Hebart, 2015	34, 34	TD	−0.00 [−0.48, 0.48]
Steding, 2023	24	TD	0.08 [−0.12, 0.27]
Gilger, 2024	98, 98	TD	0.03 [−0.25, 0.31]
Random−effects meta−analysis:			0.03 [−0.30, 0.35]

Decreased reward function | Increased reward function

−6 −4 −2 0 2 4

SMD (95% CI)